Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 637

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 637
---
 holding company for its subsidiary. On March 18, 2024, Heritas Cayco formally changed its name to OmnigenicsAI Corp. On February 26, 2024, the Company underwent an intragroup reorganization pursuant to which Heritas Ltd., an exempted company organized under the laws of the Cayman Islands, contributed to OmnigenicsAI a wholly owned subsidiary of Heritas Ltd., all the issued and outstanding shares in its subsidiary, Heritas SAU (“Heritas Argentina”) in exchange for 30,000,000 newly issued shares, making Heritas SAU a wholly owned subsidiary. Together, OmnigenicsAI and its subsidiary, Heritas SAU, are referred to as the “Group.” On March 25, 2024, the Company entered into a Business Combination Agreement (“BCA”) with APx Acquisition Corp. I (“SPAC”). The transaction includes merging a subsidiary into SPAC, converting all SPAC’s shares and warrants into OmnigenicsAI shares, pursuant to the terms of the BCA. Upon consummation of the BCA restructuring of intercompany debt will be carried out between Heritas Argentina and Heritas Ltd., which involves the forgiveness of certain intercompany loans (in whose the lender is Heritas Ltd., see Note 20), which will be accounted for as capital contributions without issuing additional equity. The Group conducts its business operations through two business segments, Heritas Diagnostics and Rewell. The Heritas Diagnostics segment provides a suite of clinical genetic tests for doctors, patients, and their families, for diagnosis, prognosis and monitoring, allowing them to make informed decisions over various conditions. These tests are distributed through exclusive partnerships with clinical laboratories, empowering them to offer these advanced diagnostic services to their customers. Heritas Diagnostics products are used for reproductive genetics, oncology, genetic and rare diseases, and human microbiome testing purposes. The Rewell segment provides patients with direct access to DNA and microbiome information to enable them to make more informed long -termhealth decisions and minimize the development of chronic diseases. This includes providing health risk information through Polygenic Risk Scores (“PRS”). Patients view their results on Rewell’s proprietary digital platform, where they can also schedule a telemedicine consultation with a healthcare professional to interpret their results and receive a health plan with recommendations. Basis of presentation and consolidation The accompanying financial statements include the combined financial results for OmnigenicsAI and Heritas Argentina for the six -monthperiods ended December 31, 2024 and 202